SCHEMBL6561744

SCHEMBL6561744

O=CN(CCc1ccc(CCNC(=O)OCc2ccccc2)nc1)OCc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KCNA5 P22460 2/20 0.42
KCNK3 O14649 1/20 0.42
KCNA3 P22001 1/20 0.42
HTT P42858 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
MAPT P10636 1/20 0.42
TGM2 P21980 1/20 0.41
IDO1 P14902 1/20 0.38
KEAP1 Q14145 2/20 0.38
NFE2L2 Q16236 2/20 0.38
PDE1B Q01064 1/20 0.37
SLC1A3 P43003 1/20 0.37
SLC1A1 P43005 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ANPEP P15144 1/20 0.36
PLAU P00749 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6563172 0.81 HTT (0.50) LMNASMN1; SMN2HTTL3MBTL1MAPT
SCHEMBL6561674 0.79 SMN1; SMN2 (0.47) LMNASMN1; SMN2HTTL3MBTL1MAPT
SCHEMBL6561783 0.79 HTT (0.53) LMNASMN1; SMN2HTTL3MBTL1MAPT
SCHEMBL6563145 0.78 LMNA (0.46) LMNASMN1; SMN2KCNA5KCNK3KCNA3
SCHEMBL4827129 0.77 TGM2 (0.60) LMNASMN1; SMN2HTTL3MBTL1MAPT
SCHEMBL160429 0.73 KCNA5 (0.67) LMNASMN1; SMN2KCNA5KCNK3KCNA3
SCHEMBL6949217 0.72 TAAR1 (0.42) IDO1MEN1KMT2A
SCHEMBL2412802 0.72 LMNA (0.53) LMNASMN1; SMN2KCNA5KCNK3KCNA3
SCHEMBL17972777 0.70 LMNA (0.61) LMNASMN1; SMN2HTTL3MBTL1MAPT
SCHEMBL2559670 0.70 LMNA (0.55) LMNASMN1; SMN2KCNA5KCNK3KCNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1296945-B1 SULFONAMIDE DERIVATIVES LILLY CO ELI (US) 2004-08-04 EP disclosed
US-6703425-B2 ADMINISTERING GLUTAMATE RECEPTOR POTENTIATOR TO TREAT PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS ELI LILLY AND COMPANY 2004-03-09 US disclosed
US-20030229102-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-11 US disclosed
EP-1296945-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2003-04-02 EP disclosed
WO-2001096289-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229102-A1 Sulfonamide derivatives GRIN1, GRIN2A, SLC1A2 LMNA 4815/4885SMN1; SMN2 208/4885KCNA5 557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.